eyeforpharma have put together an interesting and free webinar with some experts talking about the past two years under the AMNOG process.
I am posting the registration link for you to join.
Health Economics and HTA and its role in pricing and reimbursement, pipeline and in-lisencing evaluations as well as portfolio and company valuations in the biotech and pharmaceutical sector is ever increasing. While I was searching the web for various news on the topic, I actually couldn't find a blog that offers a platform of exchange among professionals in this field around the various topics - so there we go now and I hope you enjoy the information... Cheers Ulf
Post a Comment